Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor

NCT04880616 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Tremor

Interventions

DRUG: NBI-827104
DRUG: Placebo

Sponsor

Neurocrine Biosciences